Shares of Abiomed Inc. (ABMD) were down 0.04% in premarket trading on Monday after the company said it had received an emergency use authorization from the Food and Drug Administration for its Impella RP heart pump to be used in certain COVID-19 patients, including those with heart failure. The medical device had received FDA approval in 2017 to be marketed in the treatment of right ventricular failure. "Acute pulmonary embolism is clearly being recognized as a life-threatening manifestation of COVID-19," Dr. Amir Kaki, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, said in the Abiomed release. Abiomed's stock is up 31.2% year-to-date. The S&P 500 has declined 5.7% since the start of the year.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
June 01, 2020 07:42 ET (11:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.